Drugs / MV-LASV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04055454 | Sep 2019 → Mar 2020 | lassa virus infectious disease | Themis Bioscience GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MV-LASV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04055454 ↗ |
| Modality | Vaccine | “a recombinant, live-attenuated, measles-vectored Lassa fever vaccine candidate (MV-LASV)” PMID 36934733 ↗ Mar 2023 |
| Route | Intramuscular | “by intra muscular (i.m.) injection” NCT04055454 ↗ |